This study is not accepting new patients
Expanded Access to Vedolizumab for Children and Teenagers With Ulcerative Colitis or Crohn's Disease in the USA
Summary
- Eligibility
- for people ages 2 years and up (full criteria)
- Location
- at UCSF
- Dates
- study started
- Principal Investigator
- by Melvin Heyman, Dr. (ucsf)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Melvin Heyman, Dr. (ucsf)
Professor Emeritus, Pediatrics, School of Medicine. Authored (or co-authored) 334 research publications. Research interests: inflammatory bowel disease (ulcerative colitis · Crohn's disease) · Pediatric Nutrition · Pancreatitis in children (acute and chronic) · Mentoring and Career Development · Fellowship Training · Gastroesophageal Reflux Disease
Details
- Status
- not accepting new patients
- Start Date
- Sponsor
- Takeda
- Links
- more information about this trial in easy-to-understand language.
- ID
- NCT06856135
- Study Type
- Expanded Access
- Last Updated